Literature DB >> 30785029

Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases.

Kristyna Pivovarcikova1, Petr Martinek1, Petr Grossmann1, Kiril Trpkov2, Reza Alaghehbandan3, Cristina Magi-Galluzzi4, Maria Pane Foix5, Enric Condom Mundo5, Daniel Berney6, Anthony Gill7, Boris Rychly8, Kvetoslava Michalova1, Joanna Rogala9, Tomas Pitra10, Tamas Micsik11, Jiri Polivka12, Milan Hora10, Ozlem Tanas Isikci13, Sarka Skalova1, Jana Mareckova1, Michal Michal1, Ondrej Hes14.   

Abstract

Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (HLRCC)/fumarate hydratase deficient renal cell carcinoma (FHRCC) is defined by molecular genetic changes (mutation/LOH in fumarate hydratase (FH) gene). We investigated chromosomal numerical aberration pattern (CNV) in FHRCC/HLRCC using array comparative genomic hybridization analysis and low pass whole genome sequencing. Genetic analysis was successfully completed in 12 tumors. Most common chromosomal aberrations detected were a complete or partial loss of chromosome 4 (5/12 cases), chromosome 15 (4/12 cases), and chromosomes 9, 13, and 14 (each in 3/12 cases), as well as a complete or partial gain of chromosome 17 (in 4/12 cases). No chromosomal losses or gains were detected in 4 cases. Copy number variation pattern in FHRCC/HLRCC appears to be highly variable and does not provide a useful diagnostic tool in identifying these cases. Immunohistochemical staining and especially molecular genetic evaluation of FH gene mutations/LOH remain the gold standard in identifying FHRCC/HLRCC.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Chromosomal numerical aberration pattern; Fumarate hydratase deficient renal cell carcinoma; Kidney

Mesh:

Substances:

Year:  2019        PMID: 30785029     DOI: 10.1016/j.anndiagpath.2019.02.008

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  4 in total

1.  [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].

Authors:  Y F Yu; S M He; Y C Wu; S W Xiong; Q Shen; Y Y Li; F Yang; Q He; X S Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-18

2.  Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Authors:  Jack P Gleeson; Ines Nikolovski; Renzo Dinatale; Mark Zucker; Andrea Knezevic; Sujata Patil; Yasser Ged; Ritesh R Kotecha; Natalie Shapnik; Samuel Murray; Paul Russo; Jonathan Coleman; Chung Han Lee; Zsofia K Stadler; A Ari Hakimi; Darren R Feldman; Robert J Motzer; Ed Reznik; Martin H Voss; Ying-Bei Chen; Maria I Carlo
Journal:  Clin Cancer Res       Date:  2021-03-03       Impact factor: 12.531

3.  Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study.

Authors:  Ines Nikolovski; Maria I Carlo; Ying-Bei Chen; Hebert Alberto Vargas
Journal:  Cancer Imaging       Date:  2021-02-19       Impact factor: 3.909

Review 4.  Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach.

Authors:  Reza Alaghehbandan; Delia Perez Montiel; Ana Silvia Luis; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.